Literature DB >> 21166887

Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines.

Kuninobu Nakajima1, Seiji Isonishi, Misato Saito, Toshiaki Tachibana, Hiroshi Ishikawa.   

Abstract

This experiment was conducted to address the question of whether acquired paclitaxel resistance is dependent upon whether it is given as a single brief exposure or as a long-term exposure. PX2 and PX24 were established from 2008 human ovarian cancer cells by 2-h single exposure or 24-h continuous exposure to paclitaxel. PX2 acquired paclitaxel resistance faster than PX24 by twofold. Drug resistant pattern was exposure-time dependent. In 2-h exposure, PX2 showed 53.86 ± 4.96 (mean ± standard deviation [SD]) fold paclitaxel resistance while PX24 showed 9.51 ± 1.01 fold resistance (P = 0.002). In 24-h exposure, PX2 showed 2.31 ± 0.3 fold paclitaxel resistance while PX24 showed 28.17 ± 0.98 fold resistance (P = 0.040). PX2 and PX24 acquired cross-resistance to docetaxel and SN38 and the resistance degrees were significantly higher in PX2 than PX24. They displayed approximately twofold cisplatin collateral sensitivity. PX24 also displayed sensitivity to other platinum drugs, oxaliplatin and ZD0473, whereas PX2 acquired significant resistance to both of them. Although differential tubulin-isotype expressions were noted among 2008, PX2 and PX24, they were not significant. In electron microscopy, prominent, densely stained lysosomes were observed more in the resistant cells than 2008. Two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines were established. Understanding the characteristics of the differential resistance pattern could be clinically beneficial for the selection of second line chemotherapy for relapsed ovarian cancer. 2010 The Authors. Human Cell 2010 Japan Human Cell Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21166887     DOI: 10.1111/j.1749-0774.2010.00098.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  21 in total

1.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

Authors:  A D Seidman; D Hochhauser; M Gollub; B Edelman; T J Yao; C A Hudis; P Francis; D Fennelly; T A Gilewski; M E Moynahan; V Currie; J Baselga; W Tong; M O'Donaghue; R Salvaggio; L Auguste; D Spriggs; L Norton
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.

Authors:  S Ranganathan; D W Dexter; C A Benetatos; A E Chapman; K D Tew; G R Hudes
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

Review 4.  Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.

Authors:  David J Stewart; Gabriela Chiritescu; Simone Dahrouge; Srabani Banerjee; Eva M Tomiak
Journal:  Cancer Treat Rev       Date:  2007-02-05       Impact factor: 12.111

5.  Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.

Authors:  Z Zhan; S Scala; A Monks; C Hose; S Bates; T Fojo
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

6.  Association of purified thyroid lysosomes to reconstituted microtubules.

Authors:  G Mithieux; C Audebet; B Rousset
Journal:  Biochim Biophys Acta       Date:  1988-04-25

7.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

8.  A mechanism of cellular resistance to drugs that interfere with microtubule assembly.

Authors:  F R Cabral; R C Brady; M J Schibler
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

9.  Substoichiometric binding of taxol suppresses microtubule dynamics.

Authors:  W B Derry; L Wilson; M A Jordan
Journal:  Biochemistry       Date:  1995-02-21       Impact factor: 3.162

10.  A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

Authors:  S N Roy; S B Horwitz
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

View more
  3 in total

1.  A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer.

Authors:  Seiji Isonishi; Masaaki Suzuki; Hiroaki Nagano; Koichiro Takagi; Masahito Shimauchi; Masakiyo Kawabata; Kazuhiko Ochiai
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

Review 2.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Authors:  Helen M Coley; Eleftheria Hatzimichael; Sarah Blagden; Iain McNeish; Alastair Thompson; Tim Crook; Nelofer Syed
Journal:  Oncotarget       Date:  2012-01

3.  Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells.

Authors:  Jolanta Szenajch; Alicja Szabelska-Beręsewicz; Aleksandra Świercz; Joanna Zyprych-Walczak; Idzi Siatkowski; Michał Góralski; Agnieszka Synowiec; Luiza Handschuh
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.